Previous Article | Next Article ![]()
Infection and Immunity, August 1999, p. 3750-3756, Vol. 67, No. 8
Department of Infectious Diseases, St. Jude
Children's Research Hospital, Memphis, Tennessee 38105
Received 25 January 1999/Returned for modification 19 March
1999/Accepted 5 May 1999
Nitric oxide (NO) production by inducible NO synthase (iNOS) during
inflammation is an essential element of antimicrobial immunity but can
also contribute to host-induced tissue damage. Under conditions of
bacterial sepsis, large amounts of NO are produced, causing
hypotension, a critical pathological feature of septic shock. In sepsis
caused by gram-positive organisms, the bacterial factors contributing
to host NO production are poorly characterized. We show that a soluble
toxin of Streptococcus pneumoniae, pneumolysin (Pln), is a
key component initiating NO production from macrophages. In contrast to
wild-type bacteria, a mutant of S. pneumoniae lacking Pln
failed to elicit NO production from murine macrophages. Purified
recombinant Pln induced NO production at low concentrations and
independently of exogenous gamma interferon (IFN- In addition to its function as an
antimicrobial agent, neurotransmitter, and vasodilator, the reactive
gas NO exerts both beneficial and deleterious effects during sepsis and
acute inflammation, including circulatory and organ failure in septic
shock (7, 36, 40). The short half-life of a few seconds is
thought to limit the toxicity of NO for host tissues. NO is produced
from the substrate L-arginine by three enzymes: inducible
NO synthase (iNOS), characteristically found in macrophages, and two
constitutive forms, endothelial cell NO synthase and neuronal cell NO
synthase, found, respectively, in the two types of cells
(24). During infection, host inflammatory mediators and
bacterial products upregulate the expression of iNOS, whose expression
and activity are normally tightly controlled (40). Both
proinflammatory cytokines (e.g., tumor necrosis factor alpha
[TNF- The prevalence of sepsis caused by gram-positive organisms is
increasing (10). Streptococcus pneumoniae is the
major pathogen causing invasive diseases, including sepsis, meningitis,
and pneumonia (8, 33). Little is known about the components
of gram-positive bacteria responsible for the host NO response. Two
cell wall components of Staphylococcus aureus, lipoteichoic
acid and peptidoglycan, have been reported to cause induction of NO,
shock, and organ injury (6, 17). In S. pneumoniae, pneumococcal cell walls have been shown to stimulate
NO production in vitro (4, 9, 18, 28); however, the
specific component or components of pneumococci responsible for
induction of iNOS or NO production are unknown. Here we analyze which
factors of live pneumococci contribute to NO stimulation in murine
macrophages. We found that pneumolysin (Pln), a pore-forming hemolysin,
is the primary component of live pneumococci stimulating NO production
in macrophages.
Cell culture and reagents.
RAW 264.7 cells were purchased
from the American Type Culture Collection (Rockville, Md.) and were
cultured in Dulbecco minimal essential medium (DMEM) (BioWhittaker,
Walkersville, Md.) supplemented with 10% fetal bovine serum
(BioWhittaker) and 2 mM L-glutamine (Gibco BRL, Grand
Island, N.Y.) without antibiotics or indicator dye in a 37°C
incubator with 5% CO2. RAW cells were confirmed to be
negative for Mycoplasma (Geneprobe; Fisher Scientific,
Atlanta, Ga.) and endotoxin (Limulus amebocyte lysate,
QCL-1000 kit; BioWhittaker). IRF-1
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Pneumolysin, a Protein Toxin of Streptococcus
pneumoniae, Induces Nitric Oxide Production from
Macrophages
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
) priming of RAW
264.7 macrophages. However, IFN-
was essential for Pln-induced NO
production, since primary macrophages from mice lacking the IFN-
receptor or interferon regulatory factor 1, a transcription factor
essential for iNOS expression, failed to produce NO when stimulated
with Pln. In addition, Pln acts as an agonist of tumor necrosis factor
alpha and interleukin 6 production in macrophages. The properties of
Pln, previously identified as a pore-forming hemolysin, also include a
role as a general inflammatory agonist.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
] and interleukin 1 [IL-1]) and bacterial
lipopolysaccharide (LPS) can activate iNOS synergistically with gamma
interferon (IFN-
). The mechanism of iNOS regulation is well
characterized at the genetic and biochemical level. The major pathways
depend upon IFN-
-mediated upregulation of interferon regulatory
factor 1 (IRF-1) expression; IRF-1 binds to the iNOS promoter and
activates iNOS transcription synergistically with NF-
B, induced
through TNF-
, IL-1, or LPS signaling (16, 41).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
(22) and
IFN-
R
/
(15) mice were obtained from
Jackson Laboratory (Bar Harbor, Me.). IFN-
R
/
mice
are on a 129/BL6 background. IRF-1
/
mice have been
backcrossed onto the C57BL/6 background for six generations and one
further generation by P.J.M. Mice were housed and bred under
specific-pathogen-free conditions at St. Jude Children's Research
Hospital Animal Resource Center. Murine peritoneal macrophages were
harvested 4 days after intraperitoneal injection of 3 ml of 3%
thioglycolate broth. Erythrocytes were removed by hypotonic lysis, and
a sample of cells was stained following cytospin. Preparations were
>90% macrophages. Peritoneal macrophages were washed and resuspended
in RPMI medium (Gibco BRL) containing 10% fetal calf serum and plated
in 24-well plates at 2 × 106 cells per well. Adherent
monolayers were treated with the agents described in the legends to
Fig. 4 and 5 for 18 h.
-D-thiogalactopyranoside (IPTG), leupeptin,
LPS (from Escherichia coli serotype O111:B4),
phenylmethylsulfonyl fluoride (PMSF), polymyxin B (PMB), RNase,
sulfanilamide, naphthylethylenediamine dihydrochloride, and trypsin.
Recombinant mouse IFN-
was purchased from Genzyme (Cambridge,
Mass.).
Measurement of nitrite.
Nitrite is the end product of NO in
cell culture and is the substrate in the Griess reaction
(12) for quantification of NO production (13).
RAW 264.7 cells (105) were resuspended in 200 µl of DMEM
and transferred into each well of a 96-well tissue culture plate
(Costar, Cambridge, Mass.). Cells were incubated in a 5%
CO2 atmosphere at 37°C for 2 h and then primed with
0.3 to 0.5 ng of IFN-
per ml for 4 h. Bacteria were harvested
by centrifugation upon reaching an optical density at 620 nm
(OD620) of 0.5 and resuspended in DMEM. After incubation of
RAW 264.7 cells with live pneumococci, pneumococcal cell wall, purified
recombinant pneumolysin or hydrogen peroxide, the culture plates were
centrifuged at 800 × g (10 min), 100-µl aliquots of each
well were transferred into a new 96-well plate, and 100 µl of Griess
reagent was added. The Griess reagent consisted of one part 1%
sulfanilamide in 5% H3PO4 and one part 0.1%
naphthylethylenediamine dihydrochloride in distilled water. The
absorption of the purple azo dye resulting from the reaction of nitrite
with the Griess reagent was measured at 546 nm by a multichannel
spectrophotometer (Spectra Max 340; Molecular Devices, Sunnyvale,
Calif.), and nitrite concentrations were determined with a nitrite
standard curve.
Cell wall preparation.
S. pneumoniae cell wall was
prepared from strain D39 and mutant strain PLN-A as described
previously (37). Briefly, 1 liter of pneumococcal culture
was grown in C+Y medium until the OD620 was 0.5 (1.5 × 108 CFU/ml), chilled in iced ethanol, centrifuged at
4°C (4,000 × g), and resuspended in 40 ml of
ice-cold 50 mM Tris HCl (pH 7.0). This suspension was added into
boiling 5% sodium dodecyl sulfate (SDS), kept boiling for 15 min,
cooled, centrifuged (10 min, 12,000 × g), resuspended,
washed twice in 1 M NaCl, and then washed six times in distilled water.
Acid-washed glass beads equal to the volume of the pellet were added,
vigorously vortexed, then removed by a sintered glass filter. The
filtrate was centrifuged (15 min, 27,000 × g), and the
pellet containing cell wall was resuspended in 100 mM Tris (pH 7.5) and
incubated with 10 µg of DNase per ml, 50 µg of RNase per ml, and
100 µg of trypsin per ml to degrade DNA, RNA, and proteins,
respectively (25, 37). Boiling and trypsin treatment
destroyed any activity of pneumolysin in the cell wall preparation,
since pneumolysin is heat-sensitive (14, 31) and not
resistant to trypsin digestion (31). Samples were centrifuged, lyophilized, weighed, redissolved in 0.1 M Tris HCl (pH
7.5), and stored at
20°C.
Immunoblotting.
RAW 264.7 macrophages were primed with 0.3 ng of IFN-
per ml for 4 h and incubated with D39 or PLN-A
(106 CFU/ml) for 6 to 8 h. Cells were pelleted by
centrifugation, and pellets were lysed on ice in extraction buffer (1%
Triton X-100, 50 mM Tris HCl, 1 mM EDTA, 1 mM
Na3VO4, 0.1 mg of PMSF per ml, 10 µg of
leupeptin per ml). The protein extracts were boiled for 5 min,
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred to a polyvinylidene fluoride membrane. After being blocked
in Tris-buffered saline with 0.1% Tween and 5% milk, blots were
incubated with a murine monoclonal antibody specific for iNOS (1:2,000)
(Transduction Labs, Lexington, Ky.). After being rinsed, the blots were
incubated with a horseradish peroxidase-conjugated anti-mouse
immunoglobulin G antibody (1:2,000) (Bio-Rad, Hercules, Calif.). After
being washed, the blots were developed by using the ECL kit (Amersham,
Little Chalfont, Buckinghamshire, England). Peritoneal macrophages were
placed on ice after stimulation and washed with ice-cold
phosphate-buffered saline. Cells were lysed directly in SDS sample
buffer and vortexed vigorously to shear DNA. Samples were separated by
gradient SDS-PAGE and transferred to nitrocellulose. Blots were blocked
in 5% milk in phosphate-buffered saline and probed with polyclonal
anti-iNOS (1:2,000) (Biomol, Plymouth Meeting, Pa.),
anti-cyclooxygenase-2 (anti-COX-2) (1:250) (Transduction Labs),
anti-IRF-1 (1:1,000) (Santa Cruz Biotechnology, Santa Cruz, Calif.),
and anti-Grb-2 (1:1,000) (growth factor receptor-bound protein 2;
Transduction Labs). Blots were developed with enhanced chemiluminescence (see Fig. 4).
ELISA.
Cytokine levels in the cell culture medium were
determined by enzyme-linked immunosorbent assay (ELISA) with specific
reagents for IL-6 (Pharmingen, San Diego, Calif.) and TNF-
(Endogen,
Boston, Mass.) according to manufacturers' instructions.
Production and purification of recombinant Pln. DNA digestions, ligations, and gel electrophoresis were performed according to standard protocols (32). Cloning of the Pln gene was based on previously published protocols (23, 39). For plasmid preparation and purification, we used kits from Qiagen (Chatsworth, Calif.) and Promega (Wizard; Madison, Wis.). Chromosomal DNA was prepared from pneumococcus (serotype 4) as described previously (30). The full-length Pln gene was amplified by PCR with the primers lysin1 (5'-AAT CCA GGA TCC TAT TAG GAG GAG AAG ATG G-3') and lysin2 (5'-TTT TGT CTC GAG CAT TCT CCT CTC CTA G-3'), with restriction sites identified by underlining. The pET-28c vector (Novagen, Cambridge, Mass.) carrying an N- and C-terminal His-tag configuration and a kanamycin cassette was used for cloning and expression of the recombinant gene encoding Pln in E. coli. Expression was induced by the addition of IPTG (1.5 mM). The Pln protein was subjected to denaturing conditions with a lysis buffer containing 6 M guanidine and a washing and eluting buffer containing 8 M urea and then purified by binding to Ni2+ immobilized on resin according to the manufacturer's instructions (Qiagen, Valencia, Calif.). After dialysis to gradually remove urea (five times for 12 h at 4°C, in 20 mM Tris, 1 mM EDTA, 10 mM NaCl, 5 mM ditheothreitol), Pln was further purified with an ion-exchange column (HiTrapS; Pharmacia, Bridgewater, N.J.) and dialyzed again, and the levels of endotoxin were determined by the Limulus assay (Limulus amebocyte lysate, QCL-1000 kit; BioWhittaker). Hemolytic activity was verified qualitatively by dropping eluted Pln fractions on sheep blood agar plates.
| |
RESULTS |
|---|
|
|
|---|
Live D39 pneumococci induce dose- and time-dependent NO production
by murine macrophages.
Live D39 pneumococci induced
concentration-dependent (Fig. 1A) and
time-dependent (Fig. 1B) NO production in IFN-
-primed RAW 264.7 macrophages. Low concentrations of live pneumococci (initial
concentration, ~10 CFU/ml; grown to ~107 to
108 CFU/ml after 18 h of incubation) were sufficient
to induce detectable nitrite concentrations in the tissue culture
supernatants during the incubation period. NO production began after 4 to 6 h and reached its maximum level after 18 h of standard
incubation time as monitored by measurements at 3-h intervals (Fig.
1B). Immunoblotting analysis performed 6 h after incubation of the
macrophages with D39 showed iNOS protein expression and confirmed the
Griess experiments (Fig. 1C). An isogenic pneumococcal mutant strain,
PLN-A, deficient in Pln, induced only low or undetectable nitrite
activity in the Griess reaction (Fig. 1A), and markedly less iNOS
activation was indicated by immunoblotting analysis (Fig. 1C).
Untreated macrophages and macrophages primed with IFN-
(0.3 ng/ml)
were used as negative controls. This concentration of IFN-
induced
no or only minimal background activity in the Griess reaction (data not
shown). Low levels of endotoxin, 0.035 ng/ml as determined by the
Limulus amebocyte lysate assay, were detected in the
ingredients of the C+Y medium. Incubation of RAW cells with pneumococci
in the presence of PMB only marginally reduced nitrite production
(11.7% ± 7.2%, mean ± standard deviation [SD]), indicating
that endotoxin does not contribute significantly to
pneumococcus-induced NO production.
|
Purified Pln induces NO production in RAW macrophages.
The
results achieved with the PLN-A mutant suggested that Pln was critical
for NO production. Therefore, we tested if purified recombinant Pln
alone is able to induce NO production. Pln induced NO production in RAW
macrophages after 18 h in the absence of exogenous mouse
recombinant IFN-
(Fig. 2). Purified
Pln (20 µg/ml) without IFN-
priming induced an average nitrite
concentration of 32.9 µM (Fig. 2B). That is 50-fold more nitrite (on
a weight basis) than the same concentration of pneumococcal cell wall
induced with IFN-
priming (Fig. 3). In
the presence of low concentrations of IFN-
(0.3 ng/ml), nitrite
production was achieved by lower concentrations of Pln (Fig. 2A): 2.6 ng of Pln per ml induced ~10 µM nitrite (Fig. 2A). This activity is
comparable to the induction of ~16 µM nitrite by 10 ng of LPS per
ml (Fig. 2B). These results show that Pln itself can stimulate RAW
macrophages to produce NO. The LPS in the recombinant Pln preparation
(0.4 ng of endotoxin per ml in 200 µg of pneumolysin per ml) was
unlikely to contribute to NO induction for the following reasons.
Incubation of RAW macrophages with the same or higher concentrations of
LPS in the absence of IFN-
did not stimulate detectable NO
production (Fig. 2B). Also RAW cells were coincubated with Pln and PMB,
a strong inhibitor of endotoxin. In order to test the
endotoxin-inhibitory effect of PMB, RAW cells were stimulated with
IFN-
(0.3 ng/ml) and LPS (10 ng/ml) in the presence and absence of
PMB. PMB significantly reduced LPS-induced NO production under this
condition (Fig. 2B). In contrast, PMB did not significantly reduce NO
production induced by Pln independently of the priming of RAW cells
with IFN-
(0.3 ng/ml) (Fig. 2B). As a further control, Pln was
heated at 95°C for 5 min. In contrast to LPS, pneumolysin is heat
sensitive and its activity is destroyed at temperatures that are >60
to 70°C (14). After heating, the NO-inducing activity of
Pln was reduced 91% at 20 µg/ml and 99% at 5 µg/ml.
|
|
High concentrations of cell wall preparations derived from D39 and
PLN-A stimulate NO production.
Having demonstrated that Pln
stimulates NO production in RAW 264.7 macrophages, we compared the
known NO production-inducing capacity of purified pneumococcal cell
wall preparations (which do not contain pneumolysin) (4, 9, 18,
28) in order to exclude the possibility that the differences in
levels of NO production induced by live D39 and PLN-A were due to
differences in the NO production-inducing activity of liberated cell
wall fragments. High concentrations of cell wall preparations of both D39 and PLN-A stimulated in a similar fashion dose-dependent NO production in macrophages in the presence of IFN-
(Fig. 3). The endotoxin levels of the cell wall preparations were 0.031 to 0.132 ng/ml (in 1.4- to 1.7-mg/ml stock solution) due to contamination of
trypsin and RNase used for the preparation. Incubation of RAW cells
with pneumococcal cell wall in the presence of the endotoxin inhibitor
PMB reduced nitrite production by 9.3% (±9.4%), indicating that
endotoxin does not contribute significantly to cell wall-induced NO production.
Pneumolysin induces iNOS and NO through a pathway strictly
dependent on IFN-
signaling.
Addition of purified Pln to RAW
cells induced iNOS expression and NO production without the addition of
exogenous IFN-
. In contrast, iNOS expression induced by other
stimuli, for example, by LPS or TNF-
, is normally dependent on
IFN-
(16). To investigate this effect in more detail, we
tested if macrophages lacking key elements of the IFN-
signal
transduction pathway were able to produce NO in response to Pln (Fig.
4). The signal transduction pathway that
leads to iNOS expression is known in considerable detail at both the
genetic and biochemical levels (27). Minimal requirements
include NF-
B activation (via LPS or TNF-
) and an increase in
IRF-1 expression mediated by IFN-
activation of a signal transducer
and activator of transcription (STAT1) (Fig. 4D). Inflammatory
peritoneal macrophages were isolated from mice lacking either the
IFN-
receptor (IFN-
R) or IRF-1 and incubated with Pln (Fig. 4).
The results showed that IFN-
and an intact IFN-
signal
transduction pathway are essential for Pln-mediated iNOS expression.
While wild-type macrophages (derived from C57BL/6 or 129/BL6 mice) made
readily detectable iNOS in response to Pln and IFN-
, neither
IRF-1
/
nor IFN-
R
/
macrophages were
able to make iNOS in response to Pln or control stimuli such as LPS and
IFN-
. The exception was that IRF-1
/
macrophages
could make extremely small amounts of iNOS protein in response to Pln
and IFN-
. One possible reason for this is that STAT1 has been shown
to also bind to the NOS2 (the gene encoding iNOS) promoter
(11). In this scenario, STAT1 would bypass the requirement
for IRF-1 for a minor effect on iNOS levels.
|
Pneumolysin is a strong agonist of multiple macrophage
functions.
Pln appeared to provide a second signal similar to LPS
or TNF-
when iNOS expression was induced together with IFN-
(Fig. 4). To address the scope of Pln as a general agonist of macrophages, IL-6, TNF-
, and COX-2 expression was measured after stimulation of
wild-type, IRF-1
/
, or IFN-
R
/
macrophages with Pln or Pln and IFN-
. COX-2 is the induced, rate-limiting enzyme involved in prostaglandin synthesis. The results
(Fig. 5) showed that Pln can induce IL-6,
TNF-
, and COX-2 in a fashion similar to that of a general macrophage
agonist such as LPS. Interestingly, COX-2 expression in response to Pln
stimulation was dependent on IFN-
signaling (Fig. 5B), as was
TNF-
production (Fig. 5C), whereas Pln-induced IL-6 expression was
independent of IFN-
(Fig. 5A). Macrophages of each genotype made
abundant amounts of IL-6 in response to Pln. This process was partly
dependent on IRF-1. Thus, Pln can stimulate macrophages to produce
multiple inflammatory agents.
|
| |
DISCUSSION |
|---|
|
|
|---|
Pln, a hemolysin belonging to the family of thiol-activated toxins
(29), is an important pneumococcal virulence factor. We
showed that in addition to its known activities, Pln can induce iNOS
with resultant NO production. Pln was able to induce NO production in
the absence of exogenous IFN-
in the mouse macrophage cell line RAW
264.7. The amounts of Pln used in our in vitro assay are biologically
relevant in the septic state: 2.6 ng of pneumolysin per ml, equivalent
to ~2.6 × 105 CFU of pneumococci per ml
(14), induced 10 µM nitrite. During sepsis, concentrations
of
105 CFU of bacteria per ml are reached in humans
(21, 34) and up to 109 to 1010 CFU
of pneumococci per ml in mice (3), equivalent to ~10 to 100 µg of pneumolysin per ml (14) have been described. In
contrast, the large amount of cell wall required to induce NO
production is of doubtful relevance in human sepsis. A cell wall
fragment concentration of 1 µg/ml is equivalent to ~105
CFU of pneumococci per ml (37); therefore, the cell wall
concentrations necessary to induce 10 µM nitrite translated to high
concentrations of pneumococci (compare Fig. 3 and 1A): 100 to 400 µg
of cell wall fragment per ml is equivalent to 1 × 107
to 4 × 107 CFU/ml.
Other studies have implicated pneumococcal cell wall components as capable of inducing NO production (4, 9, 18, 28). However, we have demonstrated that (in the case of live microorganisms) Pln is the main inducer of NO production in macrophages. A live Pln-deficient mutant induced low or undetectable iNOS and NO production compared to its isogenic parent, D39, indicating that the amounts of cell wall fragment released during bacterial growth were not sufficient to induce substantial NO production. In contrast, incubation of macrophages with <102 CFU/ml (initial concentration, growing to ~108 CFU/ml after 18 h of incubation) of live pneumococcal strain D39 resulted in a measurable concentration of approximately 3 µM nitrite after 18 h of incubation.
We have begun to dissect the pathway(s) that Pln activates in
macrophages. Since RAW cells appeared to produce NO and have iNOS
expression that was independent of exogenous IFN-
, we tested whether
this cytokine was required by stimulating macrophages with a
genetically inactivated IFN-
signaling pathway. The results clearly
showed that IFN-
is an essential cofactor for Pln-induced iNOS
expression. The data also suggest that RAW cells can make enough
endogenous IFN-
within the cultures to activate iNOS expression when
exposed to Pln. Less likely, in our opinion, is the possibility that
the mechanism of NOS2 activation may differ between RAW
cells and primary macrophages.
In addition to our novel finding of Pln-mediated induction of iNOS, we
confirmed and extended studies demonstrating induction of TNF-
by
Pln (14). We showed that Pln also stimulated the production
of other proinflammatory mediators such as IL-6 and COX-2, the
rate-limiting enzyme responsible for induced prostanoid synthesis.
COX-2 appears to have requirements similar to those of iNOS for
induction in macrophages: IRF-1 (Fig. 5B), along with another signal
that activates the NF-
B pathway, appears to be essential. TNF-
expression is also dependent on the activation of the NF-
B pathway.
We speculate that Pln has the ability to act as a general activator of
macrophages, possibly through activation of NF-
B. Whether this
effect is direct or mediated via other agents or cytokines remains an
open question. It seems reasonable to suggest that the proinflammatory
effects of Pln may be physiologically relevant in streptococcal disease.
Pln is believed to act by binding to cholesterol in eucaryotic cell
membranes and to form transmembrane pores (2). It is conceivable that pores result in the influx of a signal substance, leading to stimulation of NOS expression and production of NO. This
pathway has been suggested as an explanation for pneumolysin-induced cochlear damage, wherein Ca2+ may induce NOS
(1). However, macrophages have a
Ca2+-independent NOS. Alternative signals, including
proinflammatory cytokines that are induced by Pln, could act as
possible secondary mediators stimulating NO production. Both IL-6 and
TNF-
are upregulated in septic shock (19, 38).
In conclusion, Pln is a novel inducer of iNOS and NO production in
macrophages that is strictly dependent on IFN-
signaling. In
addition, Pln stimulates the production of the inflammatory mediators
TNF-
and IL-6 and the expression of COX-2.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grant AI 27913, Cancer Center Support CORE grant P30 CA 21765, and the American Lebanese Syrian Associated Charities (ALSAC).
We thank Daimin Zhao for technical assistance and Elaine Tuomanen for many thoughtful discussions and suggestions and her critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105-2794. Phone: (901) 495-3486. Fax: (901) 495-3099. E-mail: johann.braun{at}stjude.org.
Editor: V. A. Fischetti
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Amaee, F. R., S. D. Comis, and M. P. Osborne. 1995. NG-Methyl-L-arginine protects the guinea pig cochlea from the cytotoxic effects of pneumolysin. Acta Oto-Laryngol. 115:386-391[Medline]. |
| 2. | Andrew, P. W., T. J. Mitchell, and P. J. Morgan. 1997. Relationship of structure to function in pneumolysin. Microb. Drug Resist. 3:11-17. [Medline] |
| 3. | Benton, K. A., M. P. Everson, and D. E. Briles. 1995. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect. Immun. 63:448-455[Abstract]. |
| 4. | Bernatowicz, A., U. Ködel, K. Frei, A. Fontana, and H. W. Pfister. 1995. Production of nitrite by primary rat astrocytes in response to pneumococci. J. Neuroimmunol. 60:53-61[Medline]. |
| 5. |
Berry, A. M.,
J. Yother,
D. E. Briles,
D. Hansman, and J. C. Paton.
1989.
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.
Infect. Immun.
57:2037-2042 |
| 6. |
De Kimpe, S. J.,
M. Kengatharan,
C. Thiemermann, and J. R. Vane.
1995.
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.
Proc. Natl. Acad. Sci. USA
92:10359-10363 |
| 7. | Fang, F. C. 1997. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Investig. 99:2818-2825[Medline]. |
| 8. | File, T. M., Jr., and J. S. Tan. 1997. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr. Opin. Pulm. Med. 3:89-97[Medline]. |
| 9. | Freyer, D., M. Weih, J. R. Weber, W. Bürger, P. Scholz, R. Manz, A. Ziegenhorn, K. Angestwurm, and U. Dirnagl. 1996. Pneumococcal cell wall components induce nitric oxide synthase and TNF-alpha in astroglial-enriched cultures. Glia 16:1-6[Medline]. |
| 10. | Friedman, G., E. Silva, and J. L. Vincent. 1998. Has the mortality of septic shock changed with time? Crit. Care Med. 26:2078-2086[Medline]. |
| 11. |
Gao, J.,
D. C. Morrison,
T. J. Parmely,
S. W. Russell, and W. J. Murphy.
1997.
An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide.
J. Biol. Chem.
272:1226-1230 |
| 12. | Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126:131-138[Medline]. |
| 13. | Hevel, J. M., and M. A. Marletta. 1994. Nitric-oxide synthase assays. Methods Enzymol. 233:250-258[Medline]. |
| 14. |
Houldsworth, S.,
P. W. Andrew, and T. J. Mitchell.
1994.
Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 by human mononuclear phagocytes.
Infect. Immun.
62:1501-1503 |
| 15. |
Huang, S.,
W. Hendriks,
A. Althage,
S. Hemmi,
H. Bluethmann,
R. Kamijo,
J. Vilcek,
R. M. Zinkernagel, and M. Aguet.
1993.
Immune response in mice that lack the interferon-gamma receptor.
Science
259:1742-1745 |
| 16. |
Kamijo, R.,
H. Harada,
T. Matsuyama,
M. Bosland,
J. Gerecitano,
D. Shapiro,
J. Le,
S. I. Koh,
T. Kimura,
S. J. Green,
T. W. Mak,
T. Taniguchi, and J. Vilcek.
1994.
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.
Science
263:1612-1615 |
| 17. |
Kengatharan, K. M.,
S. De Kimpe,
C. Robson,
S. J. Foster, and C. Thiemermann.
1998.
Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure.
J. Exp. Med.
188:305-315 |
| 18. | Kim, Y. S., and M. G. Täuber. 1996. Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production. Infect. Immun. 64:3148-3153[Abstract]. |
| 19. | Krafte-Jacobs, B., and G. H. Bock. 1996. Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock. Crit. Care Med. 24:1455-1459[Medline]. |
| 20. | Lacks, S. A., and R. D. Hotchkiss. 1960. A study of the genetic material determining an enzyme activity in pneumococcus. Biochim. Biophys. Acta 39:508-517[Medline]. |
| 21. |
La Scolea, L. J., Jr., and D. Dryja.
1984.
Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitis and its diagnostic significance.
J. Clin. Microbiol.
19:187-190 |
| 22. | Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakami, N. Watanabe, T. M. Kündig, R. Amakawa, K. Kishihara, A. Wakeham, J. Potter, C. L. Furlonger, A. Narendran, H. Suzuki, P. S. Ohashi, C. J. Paige, T. Taniguchi, and T. W. Mak. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75:83-97[Medline]. |
| 23. | Mitchell, T. J., J. A. Walker, F. K. Saunders, P. W. Andrew, and G. J. Boulnois. 1989. Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties. Biochim. Biophys. Acta 1007:67-72[Medline]. |
| 24. | Moncada, S., R. M. Palmer, and E. A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:109-142[Medline]. |
| 25. |
Mosser, J. L., and A. Tomasz.
1970.
Choline-containing teichoic acid as a structural component of pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme.
J. Biol. Chem.
245:287-298 |
| 25a. | Murray, P. J. Unpublished data. |
| 26. | Nagase, S., K. Takemura, A. Ueda, A. Hirayama, K. Aoyagi, M. Kondoh, and A. Koyama. 1997. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine. Biochem. Biophys. Res. Commun. 233:150-153[Medline]. |
| 27. |
Nathan, C., and Q.-W. Xie.
1994.
Regulation of biosynthesis of nitric oxide.
J. Biol. Chem.
269:13725-13728 |
| 28. | Orman, K. L., J. L. Shenep, and B. K. English. 1998. Pneumococci stimulate the production of the inducible nitric oxide synthase and nitric oxide by murine macrophages. J. Infect. Dis. 178:1649-1657[Medline]. |
| 29. | Paton, J. C. 1996. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol. 4:103-106[Medline]. |
| 30. | Pearce, B. J., Y. B. Yin, and H. R. Masure. 1993. Genetic identification of exported proteins in Streptococcus pneumoniae. Mol. Microbiol. 9:1037-1050[Medline]. |
| 31. |
Rubins, J. B.,
P. G. Duane,
D. Charboneau, and E. N. Janoff.
1992.
Toxicity of pneumolysin to pulmonary endothelial cells in vitro.
Infect. Immun.
60:1740-1746 |
| 32. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 33. |
Schuchat, A.,
K. Robinson,
J. D. Wenger,
L. H. Harrison,
M. Farley,
A. L. Reingold,
L. Lefkowitz, and B. A. Perkins.
1997.
Bacterial meningitis in the United States in 1995.
N. Engl. J. Med.
337:970-976 |
| 34. | Shenep, J. L., P. M. Flynn, F. F. Barrett, G. L. Stidham, and D. F. Westenkirchner. 1988. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J. Infect. Dis. 157:565-568[Medline]. |
| 35. | Spellerberg, B., D. R. Cundell, J. Sandros, B. J. Pearce, I. Idäpään-Heikkilä, C. Rosenow, and H. R. Masure. 1996. Pyruvate oxidase as a determinant of virulence in Streptococcus pneumoniae. Mol. Microbiol. 19:803-813[Medline]. |
| 36. | Thiemermann, C. 1997. Nitric oxide and septic shock. Gen. Pharmacol. 29:159-166[Medline]. |
| 37. | Tuomanen, E., H. Liu, B. Hengstler, O. Zak, and A. Tomasz. 1985. The induction of meningeal inflammation by components of the pneumococcal cell wall. J. Infect. Dis. 151:859-868[Medline]. |
| 38. | Waage, A. 1998. Tumour necrosis factor and septic shock. Lancet 351:603[Medline]. |
| 39. |
Walker, J. A.,
R. L. Allen,
P. Falmagne,
M. K. Johnson, and G. J. Boulnois.
1987.
Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae.
Infect. Immun.
55:1184-1189 |
| 40. | Wong, J. M., and T. R. Billiar. 1995. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv. Pharmacol. 34:155-170. |
| 41. |
Xie, Q. W.,
Y. Kashiwabara, and C. Nathan.
1994.
Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase.
J. Biol. Chem.
269:4705-4708 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»